Moreover, the mode of action of LGALS9-CD45 between tumor cells and T cells and the mode of action of LGALS9-CD44 between tumor cells and B cells in low subgroups of patients belong to the immunosuppressive pathway, which can be used as a potential immunotherapeutic target in the low group [40]. This evidence concerns the gene PTPRC and neoplasm.